Targeted radiation therapy for DLL3-positive advanced cancers
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new targeted radiation therapy (called [225Ac]Ac-ETN029) for people with advanced cancers that have a protein called DLL3 on their cells. The treatment is designed to deliver radiation directly to cancer cells, and the goal is to see if it is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have advanced small cell lung cancer, large cell neuroendocrine lung cancer, neuroendocrine prostate cancer, or a neuroendocrine tumor in the digestive system that has spread or cannot be removed.
- Your cancer has gotten worse after at least one standard treatment (like chemotherapy), or you could not tolerate that treatment.
- For some cancer types, you need a special scan showing the study drug collects in your tumor.
- You must have a tumor that can be measured on a CT scan or MRI.
- You do not have severe kidney problems, uncontrolled urinary issues, or active brain metastases needing treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines radiation with an immunotherapy drug called tarlatamab to treat cancers that make a protein called DLL3. The goal is to see if this combination works better than either treatment alone for people with certain types of lung cancer and other tumors that have not responded to prior therapy.
This trial tests a special PET/CT imaging scan that may help doctors find where small cell lung cancer (and some related tumors) are in the body using a DLL3 target. It’s a Phase 1/2 study, mainly to see how well the scan detects tumors and guides care.
This Phase 2 study tests how different doses of BI 764532 affect people with small cell lung cancer or certain other neuroendocrine cancers. It may help shrink tumors and improve symptoms after standard treatments have stopped working.
This trial tests a new drug called MP0712 that delivers radiation directly to cancer cells that have a marker called DLL3. It is for people with small cell lung cancer or other solid tumors that express DLL3, whose cancer has come back after prior treatments.
This trial tests a new drug called 177Lu-DTPA-SC16.56, which delivers radiation directly to cancer cells that have a specific marker called DLL3. It is for people with high-grade neuroendocrine lung or prostate cancer that has spread and gotten worse after at least one round of chemotherapy.
This trial uses a special PET/CT scan that targets a substance called DLL3, found on some cancer cells, to see if doctors can better detect or monitor neuroendocrine carcinoma. It may help you and your doctor get clearer information about your cancer.
Hear when a new Small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.